The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy ...

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy ...

Ltd., will present updated data on cenobamate, an anti-seizure medication, at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, December 6-10, 2024. The company ...

Our research will contribute information that highlights cenobamate's potential as a treatment option covering diverse aspects of cenobamate's efficacy, safety, and mechanism of action." ...